Fig 1: lncRNA MAPKAPK5-AS1 promotes thyroid cancer progression by targeting miR-519e-5p/YWHAH. A) RT-qPCR assay was implemented to certify transfection efficiency for miR-519e-5p inhibitor and MAPKAPK5-AS1 siRNAs. B-F) CCK-8, EdU, flow cytometry, wound healing, and transwell assays were employed to estimate the role of the MAPKAPK5-AS1/miR-519e-5p/YWHAH axis in BCPAP cell proliferation, migration, invasion and apoptosis; **p<0.01 vs sh-NC + NC inhibitor, ##p<0.01 vs sh-MAPKAPK5- AS1 + NC inhibitor, ?p<0.01 vs sh-MAPKAPK5-AS1 + miR-519e-5p inhibitor.
Fig 2: YWHAH is a downstream target of miR-519e-5p. A) Putative miR-519e-5p binding sites in the 3’UTR of YWHAH. () A luciferase reporter assay was implemented to certify the association between miR-519e-5p and YWHAH. C-E) RT-qPCR, Western blot and immunofluorescence analyses were used to determine the effects of miR-519e-5p mimic on YWHAH mRNA and protein levels. F) Expression of YWHAH was detected in thyroid cancer cell lines; **p<0.01 vs NC mimic.
Supplier Page from Abcam for Anti-14-3-3 eta/YWHAH antibody [3G12]